Retrospective cohort study of the effectiveness of the Sputnik V and EpiVacCorona vaccines against the SARS-CoV-2 Delta variant in Moscow (June-July 2021)

Матвеева, О. В.; Ershov, Alexander

doi:10.21203/rs.3.rs-1700347/v1

Cited by 7 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A meta-analysis of many studies shows similar effectiveness of the mRNA-based vaccines among themselves (6) and with the two-dose adenovirus-based vaccine produced by AstraZeneca (5,7). Some studies show that the Sputnik V vaccine was just as effective (8). However, there is evidence that mRNA-based vaccines are more effective than the single-dose adenovirus vectorbased vaccine produced by Johnson & Johnson (9).…”

Section: Introductionmentioning

confidence: 99%

Comparison of Vaccination and Booster Rates and Their Impact on Excess Mortality During the COVID-19 Pandemic in European Countries

Matveeva¹,

Shabalina

2023

Preprint

Self Cite

View full text Add to dashboard Cite

Aim To evaluate the effect of vaccination/booster administration dynamics on the reduction of excess mortality during COVID-19 infection waves in European countries. Methods We selected twenty-nine countries from the OurWorldInData project database according to their population size of more than one million and the availability of information on dominant SARS-CoV-2 variants during COVID-19 infection waves. After selection, we categorized countries according to their ″faster″ or ″slower″ vaccination rates. The first category included countries that reached 60% of vaccinated residents by October 2021 and 70% by January 2022. The second or ″slower″ category included all other countries. In the first or ″faster″ category, two groups, ″boosters faster'' and ″boosters slower″ were created. Pearson correlation analysis, linear regression, and chi-square test for categorical data were used to identify the association between vaccination rate and excess mortality. We chose time intervals corresponding to the dominance of viral variants: Wuhan, Alpha, Delta, and Omicron BA.1/2. Results The ″faster″ countries, as opposed to the ″slower″ ones, did better in protecting their residents from mortality during all periods of the SARS-CoV-2 pandemic and even before vaccination. Perhaps higher GDP per capita contributed to their better performance throughout the pandemic. During mass vaccination, when the Delta variant prevailed, the contrast in mortality rates between the ″faster″ and ″slower″ categories was strongest. The average excess mortality in the ″slower″ countries was nearly 5 times higher than in the ″faster″ countries, and the odds ratio (OR) was 4.9 (95% CI 4.4 to 5.4). Slower booster rates were associated with significantly higher mortality during periods dominated by Omicron BA.1 and BA.2, with an OR of 2.6 (CI 95%. 2.1 to 3.3). Among the European countries we analyzed, Denmark, Norway, and Ireland did best, with a pandemic mortality rate of 0.1% of the population or less. By comparison, Bulgaria, Serbia, and Russia had a much higher mortality rate of up to 1% of the population. Thus, slow vaccination and booster administration was a major factor contributing to an order of magnitude higher excess mortality in ″slower″ European countries compared to more rapidly immunized countries.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison of Vaccination and Booster Rates and Their Impact on Excess Mortality During the COVID-19 Pandemic in European Countries

Matveeva¹,

Shabalina

2023

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, all input data, calculations and the code are available in GitHub [ 59 ]. The content of the manuscript has previously appeared online in ResearchSquare preprint [ 60 ].…”

mentioning

confidence: 99%

Retrospective Cohort Study of the Effectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARS-CoV-2 Delta Variant in Moscow (June–July 2021)

Matveeva¹,

Ershov²

2022

Vaccines

Self Cite

View full text Add to dashboard Cite

The goal of this study was to evaluate the epidemiological effectiveness of the Sputnik V and EpiVacCorona vaccines against COVID-19. This work is a retrospective cohort study of COVID-19 patients. The cohort created by the Moscow Health Department included more than 300,000 infected people who sought medical care in June and July 2021. Analysis of data revealed a tendency for the increase in the Sputnik V vaccine effectiveness (VE) as the severity of the disease increased. Protection was the lowest for mild disease, and it was more pronounced for severe disease. We also observed a decrease in VE with increasing age. For the youngest group (18–50 years old), the estimated VE in preventing death in June 2021 was 95% (95% CI 64–100), and for the older group (50+ years old), it was 74% (95% CI 67–87). The estimated protection against a severe form of the disease in the 18–50-year-old group was above 81% (CI 95% 72–93), and in the 50+ years-old group, it was above 68% (CI 95% 65–82). According to our analysis, EpiVacCorona proved to be an ineffective vaccine and therefore cannot protect against COVID-19.

show abstract

Data and distrust hamper Russia’s vaccination programme

Loseva¹

2022

BMJ

View full text Add to dashboard Cite

Retrospective cohort study of the effectiveness of the Sputnik V and EpiVacCorona vaccines against the SARS-CoV-2 Delta variant in Moscow (June-July 2021)

Cited by 7 publications

References 0 publications

Comparison of Vaccination and Booster Rates and Their Impact on Excess Mortality During the COVID-19 Pandemic in European Countries

Comparison of Vaccination and Booster Rates and Their Impact on Excess Mortality During the COVID-19 Pandemic in European Countries

Retrospective Cohort Study of the Effectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARS-CoV-2 Delta Variant in Moscow (June–July 2021)

Data and distrust hamper Russia’s vaccination programme

Contact Info

Product

Resources

About